Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCART123 in BPDCN
NCT03203369Phase 1Terminated
- Sponsor
- Cellectis
- Start
- Jun 2017
- Primary completion
- Jun 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of UCART123 in Blastic plasmacytoid dendritic cell neoplasm (BPDCN) (2 arms), sponsored by Cellectis. Primary endpoint: Incidence, nature, and severity of adverse events and serious adverse events at Day 84. Started Jun 2017; status: terminated.
02
Drugs
UCART123
03
Conditions
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NCT03203369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03203369.